The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform
Kenneth A Holroyd - One of the best experts on this subject based on the ideXlab platform.
-
pericranial muscle tenderness and exteroceptive suppression of temporalis muscle activity a blind study of Chronic Tension type Headache
Headache, 1997Co-Authors: Kenneth A Holroyd, Michelle GreerAbstract:The aim of the present study was to examine the ability of pericranial muscle tenderness and the second exteroceptive suppression period to distinguish Chronic Tension-type Headache sufferers, migraine sufferers, and controls in a young adult population utilizing a blind design. The second exteroceptive suppression periods were assessed using the methodology recommended by the European Headache Federation and were scored with an automatec computer software program designed in our laboratory to provide reliable, standardized, and precise quantification of exteroceptive suppression periods and eliminate any influence of experimenter bias that may occur with manual scoring. Our sample consisted of 45 subjects diagnosed according to IHS criteria: 25 with Chronic Tension-type Headache and 20 with migraine without aura. Twenty-three Headache-free controls were recruited. Consistent with our previous findings, abnormalities in pericranial muscle-tenderness, but not in the second exteroceptive suppression period distinguished Chronic Tension-type Headache sufferers from controls. The Chronic Tension Headache sufferers exhibited the highest pericranial muscle tenderness and the control group exhibited the lowest tenderness (p<.001). Pericranial muscle tenderness was quite successful in distinguishing recurrent Headache sufferers from controls, but failed to distinguish Chronic Tension-type Headache sufferers from migraineurs. Our findings raise the possibility that pericranial muscle tenderness is present early in the development of Chronic Tension-type Headache and migraine without aura, and thus might contribute to the etiology of Headache disorders. Our findings also indicate that a shortened second exteroceptive suppression period is not a reliable marker for Chronic Tension-type Headache in young adults.
-
change mechanisms associated with combined relaxation emg biofeedback training for Chronic Tension Headache
Applied Psychophysiology and Biofeedback, 1997Co-Authors: Lori A. Rokicki, Steven Kvaal, Kenneth A Holroyd, Gay L. LipchikAbstract:Therapeutic mechanisms hypothesized to underlie improvements in Tension Headache activity achieved with combined relaxation and electromyographic (EMG) biofeedback therapy were examined. These therapeutic mechanisms included (1) changes in EMG activity in frontal and trapezii muscles, (2) changes in central pain modulation as indexed by the duration of the second exteroceptive silent period (ES2), and (3) changes in Headache locus of control and self-efficacy. Forty-four young adults with Chronic Tension-type Headaches were assigned either to six sessions of relaxation and EMG biofeedback training (N = 30) or to an assessment only control group (N = 14) that required three assessment sessions. Measures of self-efficacy and locus of control were collected at pre- and posttreatment, and ES2 was evaluated at the beginning and end of the first, third, and last session. EMG was monitored before, during, and following training trials. Relaxation/EMG biofeedback training effectively reduced Headache activity: 51.7% of subjects who received relaxation/biofeedback therapy recorded at least a 50% reduction in Headache activity following treatment, while controls failed to improve on any measure. Improvements in Headache activity in treated subjects were correlated with increases in self-efficacy induced by biofeedback training but not with changes in EMG activity or in ES2 durations. These results provide additional support for the hypothesis that cognitive changes underlie the effectiveness of relaxation and biofeedback therapies, at least in young adult Tension-type Headache sufferers.
-
Change Mechanisms Associated with Combined Relaxation/EMG Biofeedback Training for Chronic Tension Headache
Applied Psychophysiology and Biofeedback, 1997Co-Authors: Lori A. Rokicki, Kenneth A Holroyd, Christopher R. France, Gay L. Lipchik, Janis L. France, Steven KvaalAbstract:Therapeutic mechanisms hypothesized to underlie improvements in Tension Headache activity achieved with combined relaxation and eleclromyographic (EMG) biofeedback therapy were examined. These therapeutic mechanisms included (1) changes in EMG activity in frontal and trapezii muscles, (2) changes in central pain modulation as indexed by the duration of the second exteroceptive silent period (ES2), and (3) changes in Headache locus of control and self-efficacy. Forty-four young adults with Chronic Tension-type Headaches were assigned either to six sessions of relaxation and EMG biofeedback training ( N = 30) or to an assessment only control group ( N = 14) that required three assessment sessions. Measures of self-efficacy and locus of control were collected at pre- and posttreatment, and ES2 was evaluated at the beginning and end of the first, third, and lost session. EMG was monitored before, during, and following training trials. Relaxation/EMG biofeedback training effectively reduced Headache activity: 51.7% of subjects who received relaxation/biofeedback therapy recorded at least a 50% reduction in Headache activity following treatment, while controls failed to improve on any measure. Improvements in Headache activity in treated subjects were correlated with increases in self-efficacy induced by biofeedback training but not with changes in EMG activity or in ES2 durations. These results provide additional support for the hypothesis that cognitive changes underlie the effectiveness of relaxation and biofeedback therapies, at least in young adult Tension-type Headache sufferers.
-
Central and peripheral mechanisms in Chronic Tension-type Headache
Pain, 1996Co-Authors: Kenneth A Holroyd, Steven Kvaal, Gary E. Cordingley, Lori A. Rokicki, David Segal, Heidi R. MccoolAbstract:Abstract The second exteroceptive suppression of masseter muscle activity (ES2) and tenderness in pericranial muscles were evaluated in 112 young adults who met IRS criteria in the following diagnostic classifications: 31 Chronic Tension Headache, 31 episodic Tension Headache, 33 migraine without aura and 17 migraine with aura. An additional 31 subjects served as controls. Pericranial muscle tenderness better distinguished diagnostic subgroups and better distinguished recurrent Headache sufferers from controls than did masseter ES2. Chronic Tension Headache sufferers exhibited the highest pericranial muscle tenderness, and controls exhibited the lowest tenderness (P
Steven Kvaal - One of the best experts on this subject based on the ideXlab platform.
-
change mechanisms associated with combined relaxation emg biofeedback training for Chronic Tension Headache
Applied Psychophysiology and Biofeedback, 1997Co-Authors: Lori A. Rokicki, Steven Kvaal, Kenneth A Holroyd, Gay L. LipchikAbstract:Therapeutic mechanisms hypothesized to underlie improvements in Tension Headache activity achieved with combined relaxation and electromyographic (EMG) biofeedback therapy were examined. These therapeutic mechanisms included (1) changes in EMG activity in frontal and trapezii muscles, (2) changes in central pain modulation as indexed by the duration of the second exteroceptive silent period (ES2), and (3) changes in Headache locus of control and self-efficacy. Forty-four young adults with Chronic Tension-type Headaches were assigned either to six sessions of relaxation and EMG biofeedback training (N = 30) or to an assessment only control group (N = 14) that required three assessment sessions. Measures of self-efficacy and locus of control were collected at pre- and posttreatment, and ES2 was evaluated at the beginning and end of the first, third, and last session. EMG was monitored before, during, and following training trials. Relaxation/EMG biofeedback training effectively reduced Headache activity: 51.7% of subjects who received relaxation/biofeedback therapy recorded at least a 50% reduction in Headache activity following treatment, while controls failed to improve on any measure. Improvements in Headache activity in treated subjects were correlated with increases in self-efficacy induced by biofeedback training but not with changes in EMG activity or in ES2 durations. These results provide additional support for the hypothesis that cognitive changes underlie the effectiveness of relaxation and biofeedback therapies, at least in young adult Tension-type Headache sufferers.
-
Change Mechanisms Associated with Combined Relaxation/EMG Biofeedback Training for Chronic Tension Headache
Applied Psychophysiology and Biofeedback, 1997Co-Authors: Lori A. Rokicki, Kenneth A Holroyd, Christopher R. France, Gay L. Lipchik, Janis L. France, Steven KvaalAbstract:Therapeutic mechanisms hypothesized to underlie improvements in Tension Headache activity achieved with combined relaxation and eleclromyographic (EMG) biofeedback therapy were examined. These therapeutic mechanisms included (1) changes in EMG activity in frontal and trapezii muscles, (2) changes in central pain modulation as indexed by the duration of the second exteroceptive silent period (ES2), and (3) changes in Headache locus of control and self-efficacy. Forty-four young adults with Chronic Tension-type Headaches were assigned either to six sessions of relaxation and EMG biofeedback training ( N = 30) or to an assessment only control group ( N = 14) that required three assessment sessions. Measures of self-efficacy and locus of control were collected at pre- and posttreatment, and ES2 was evaluated at the beginning and end of the first, third, and lost session. EMG was monitored before, during, and following training trials. Relaxation/EMG biofeedback training effectively reduced Headache activity: 51.7% of subjects who received relaxation/biofeedback therapy recorded at least a 50% reduction in Headache activity following treatment, while controls failed to improve on any measure. Improvements in Headache activity in treated subjects were correlated with increases in self-efficacy induced by biofeedback training but not with changes in EMG activity or in ES2 durations. These results provide additional support for the hypothesis that cognitive changes underlie the effectiveness of relaxation and biofeedback therapies, at least in young adult Tension-type Headache sufferers.
-
Central and peripheral mechanisms in Chronic Tension-type Headache
Pain, 1996Co-Authors: Kenneth A Holroyd, Steven Kvaal, Gary E. Cordingley, Lori A. Rokicki, David Segal, Heidi R. MccoolAbstract:Abstract The second exteroceptive suppression of masseter muscle activity (ES2) and tenderness in pericranial muscles were evaluated in 112 young adults who met IRS criteria in the following diagnostic classifications: 31 Chronic Tension Headache, 31 episodic Tension Headache, 33 migraine without aura and 17 migraine with aura. An additional 31 subjects served as controls. Pericranial muscle tenderness better distinguished diagnostic subgroups and better distinguished recurrent Headache sufferers from controls than did masseter ES2. Chronic Tension Headache sufferers exhibited the highest pericranial muscle tenderness, and controls exhibited the lowest tenderness (P
Paolo Martelletti - One of the best experts on this subject based on the ideXlab platform.
-
A one-year prospective costing study of botulinum toxin type A treatment of Chronic Tension Headache
The Journal of Headache and Pain, 2004Co-Authors: Fabio Palazzo, Francesco S. Mennini, Laura Fioravanti, Laura Piasini, Gabriella Coloprisco, Paolo MartellettiAbstract:The objective was to measure the cost of botulinum toxin type A (BTX-A) treatment of Chronic Tension-type Headache. A prospective pharmaceutical costing analysis was completed in the Day Hospital of the Regional Referral Headache Centre at Sant’Andrea Hospital in Rome, Chronic Tension-type Headache patients were treated from February 2003 to January 2004. Patients were treated with 100 U of BTX-A every three months for one year by using the Fixed Doses Fixed Sites procedure. The cost of treatment was based on drug acquisition costs, supplies and professional time needed to administer treatment. The average cost of conventional Headache medications was € 853.43 before BTX-A treatment, and € 450.47 after. The cost of BTX-A treatment was € 642.00. Adding the cost of adjunctive conventional medications brought the total cost of BTX-A treatment to € 1092.47. BTX-A treatment reduced use of conventional Headache medications and expenditures although the net cost of treatment increased with BTX-A use.
-
A one-year retrospective economic evaluation of botulinum toxin type A treatment of Chronic Tension Headache
The Journal of Headache and Pain, 2004Co-Authors: Francesco S. Mennini, Laura Fioravanti, Laura Piasini, Fabio Palazzo, Gabriella Coloprisco, Paolo MartellettiAbstract:The objective was to measure the impact of botulinum toxin type A (BTX-A) treatment on symptoms and medication utilisation patterns in patients with Chronic Tension-type Headache. A retrospective chart analysis was completed in the Day Hospital of the Regional Referral Headache Centre at Sant’Andrea Hospital in Rome. Clinical charts were randomly selected for 100 patients treated from February 2002 to January 2003. Patients were treated with 100 U of BTX-A every three months for one year by using the Fixed Doses Fixed Sites procedure. Treatment outcome ranged from complete resolution of Headache symptoms to a worsening of symptoms resulting in discontinuation. Headache medication use before and after treatment was analysed. After BTX-A treatment, 85% of patients experienced at least some degree of pain relief and reduced their use of analgesics. The reduced percentages of patients using a variety of Headache medications after BTX-A treatment results from a reduction in their Headache symptoms.
-
Reduction in expenditures on analgesics during one year of treatment of Chronic Tension Headache with BoNT-A
The Journal of Headache and Pain, 2003Co-Authors: G. Coloprisco, Sergio De Filippis, Pier Giorgio Santi, Giuseppe Fiore, Anna Rodio, Paolo MartellettiAbstract:The aim of this study was to investigate the impact of the use of botulinum toxin type A (BoNT-A; BOTOX; Allergan, Inc.; Irvine, CA) as preventive treatment of Chronic Tension-type Headache (CTH) on analgesic use and expenditure. This was a prospective, single-center, 1-year, open-label study of the effect of BoNT-A treatment on acute analgesic use and expenditure in CTH patients. A structured Headache questionnaire, which included questions about medication costs, was completed by CTH patients attending a specialist Headache clinic in Rome prior to BoNT-A injections. Repeat injections were administered every 3 months for up to 1 year. Patients were required to complete the questionnaire prior to each injections cycle. A pharmacoeconomic analysis was performed at each assessment to determine the effect of BoNT-A treatment on analgesic use and expenditure. Three hundred questionnaire were distributed and 296 (98%) were completed. The study population consisted of 67.8% (201) females and 32.2% (95) males, with a mean age of 46.7±16.1 years. The economic evaluation of the pharmacologic treatment of CTTH was conducted on the 101 (34.12%) patients who gave complete information on posology. Pharmacoeconomic data analysis focused on the whole group using analgesics compared to those who self-prescribed and those who turned to health specialists before and after treatment with BoNT-A. Prior to treatment with BoNT-A the median monthly pharmaceutic expenditure per patient was euro (€) 24.30 for the whole group using analgesics, and € 34.93 and € 18.51 for the “self-prescribers” and the “prescribed by specialist” groups, respectively. Median monthly pharmaceutic expenditure decreased significantly for the whole group (p
-
Epidural corticosteroid blockade in cervicogenic Headache
European Review for Medical and Pharmacological Sciences, 1998Co-Authors: Paolo Martelletti, Di Sabato F, Alampi D, Apponi F, Borgonuovo P, Granata M, Chiara Reale, Mario GiacovazzoAbstract:Cervicogenic Headache (CGH) is a relatively common form of Headache stem- ming from the neck structures which presents some pathophysiological condition probably linked together with various pain-producing fac- tors. This report presents a series of 9 patients suffering from cervicogenic Headache and the results achieved by means of epidural steroid (methylprednisolone 40 mg) injection into the epidural cervical space (C6-C7 or C7-T1) level. The effectiveness of this diagnostic blockade was compared with the results obtained using the same procedure in 6 Chronic Tension Headache (CTH) patients. A sharp decrease in the Numeric Intensity Scale (NIS) and in the Drug Consumption Index (DCI) values were ob- served after the diagnostic procedure in CGH patients. The short-term (12 hours) and medium- term (4 weeks) marked clinical improvement ob- tained in CGH patients may increase the number of available diagnostic tools which can be used to identify these underestimated patients popu- lation. The long-term effectiveness of this ap- proach in cervicogenic patients is beeing evalu- ated over time.
-
Epidural corticosteroid blockade in cervicogenic Headache.
European review for medical and pharmacological sciences, 1998Co-Authors: Paolo Martelletti, Apponi F, Borgonuovo P, Chiara Reale, F. Di Sabato, M. Granata, D. Alampi, Mario GiacovazzoAbstract:Cervicogenic Headache (CGH) is a relatively common form of Headache stemming from the neck structures which presents some pathophysiological condition probably linked together with various pain-producing factors. This report presents a series of 9 patients suffering from cervicogenic Headache and the results achieved by means of epidural steroid (methylprednisolone 40 mg) injection into the epidural cervical space (C6-C7 or C7-T1) level. The effectiveness of this diagnostic blockade was compared with the results obtained using the same procedure in 6 Chronic Tension Headache (CTH) patients. A sharp decrease in the Numeric Intensity Scale (NIS) and in the Drug Consumption Index (DCI) values were observed after the diagnostic procedure in CGH patients. The short-term (12 hours) and medium-term (4 weeks) marked clinical improvement obtained in CGH patients may increase the number of available diagnostic tools which can be used to identify these underestimated patients population. The long-term effectiveness of this approach in cervicogenic patients is being evaluated over time.
Lori A. Rokicki - One of the best experts on this subject based on the ideXlab platform.
-
change mechanisms associated with combined relaxation emg biofeedback training for Chronic Tension Headache
Applied Psychophysiology and Biofeedback, 1997Co-Authors: Lori A. Rokicki, Steven Kvaal, Kenneth A Holroyd, Gay L. LipchikAbstract:Therapeutic mechanisms hypothesized to underlie improvements in Tension Headache activity achieved with combined relaxation and electromyographic (EMG) biofeedback therapy were examined. These therapeutic mechanisms included (1) changes in EMG activity in frontal and trapezii muscles, (2) changes in central pain modulation as indexed by the duration of the second exteroceptive silent period (ES2), and (3) changes in Headache locus of control and self-efficacy. Forty-four young adults with Chronic Tension-type Headaches were assigned either to six sessions of relaxation and EMG biofeedback training (N = 30) or to an assessment only control group (N = 14) that required three assessment sessions. Measures of self-efficacy and locus of control were collected at pre- and posttreatment, and ES2 was evaluated at the beginning and end of the first, third, and last session. EMG was monitored before, during, and following training trials. Relaxation/EMG biofeedback training effectively reduced Headache activity: 51.7% of subjects who received relaxation/biofeedback therapy recorded at least a 50% reduction in Headache activity following treatment, while controls failed to improve on any measure. Improvements in Headache activity in treated subjects were correlated with increases in self-efficacy induced by biofeedback training but not with changes in EMG activity or in ES2 durations. These results provide additional support for the hypothesis that cognitive changes underlie the effectiveness of relaxation and biofeedback therapies, at least in young adult Tension-type Headache sufferers.
-
Change Mechanisms Associated with Combined Relaxation/EMG Biofeedback Training for Chronic Tension Headache
Applied Psychophysiology and Biofeedback, 1997Co-Authors: Lori A. Rokicki, Kenneth A Holroyd, Christopher R. France, Gay L. Lipchik, Janis L. France, Steven KvaalAbstract:Therapeutic mechanisms hypothesized to underlie improvements in Tension Headache activity achieved with combined relaxation and eleclromyographic (EMG) biofeedback therapy were examined. These therapeutic mechanisms included (1) changes in EMG activity in frontal and trapezii muscles, (2) changes in central pain modulation as indexed by the duration of the second exteroceptive silent period (ES2), and (3) changes in Headache locus of control and self-efficacy. Forty-four young adults with Chronic Tension-type Headaches were assigned either to six sessions of relaxation and EMG biofeedback training ( N = 30) or to an assessment only control group ( N = 14) that required three assessment sessions. Measures of self-efficacy and locus of control were collected at pre- and posttreatment, and ES2 was evaluated at the beginning and end of the first, third, and lost session. EMG was monitored before, during, and following training trials. Relaxation/EMG biofeedback training effectively reduced Headache activity: 51.7% of subjects who received relaxation/biofeedback therapy recorded at least a 50% reduction in Headache activity following treatment, while controls failed to improve on any measure. Improvements in Headache activity in treated subjects were correlated with increases in self-efficacy induced by biofeedback training but not with changes in EMG activity or in ES2 durations. These results provide additional support for the hypothesis that cognitive changes underlie the effectiveness of relaxation and biofeedback therapies, at least in young adult Tension-type Headache sufferers.
-
Central and peripheral mechanisms in Chronic Tension-type Headache
Pain, 1996Co-Authors: Kenneth A Holroyd, Steven Kvaal, Gary E. Cordingley, Lori A. Rokicki, David Segal, Heidi R. MccoolAbstract:Abstract The second exteroceptive suppression of masseter muscle activity (ES2) and tenderness in pericranial muscles were evaluated in 112 young adults who met IRS criteria in the following diagnostic classifications: 31 Chronic Tension Headache, 31 episodic Tension Headache, 33 migraine without aura and 17 migraine with aura. An additional 31 subjects served as controls. Pericranial muscle tenderness better distinguished diagnostic subgroups and better distinguished recurrent Headache sufferers from controls than did masseter ES2. Chronic Tension Headache sufferers exhibited the highest pericranial muscle tenderness, and controls exhibited the lowest tenderness (P
I Karakulova - One of the best experts on this subject based on the ideXlab platform.
-
EHMTI-0299. Serotonin as biomarker of ache intensity in Chronic Tension Headache
Journal of Headache and Pain, 2014Co-Authors: I KarakulovaAbstract:Tension Headache (TH) belongs to most frequent type of the idiopathic cephalalgies. Depression and serotonins metabolism disorders play a leading role in the pathogenesis of TH.